GSE122618

Circulating miR 218-5p, alone or in combination, predicts corticosteroid failure in ulcerative colitis. Study through computational strategies based on Systems Biology.

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Our group used rectal biopsies from patients with active ulcerative colitis (UC) and differential response to glucocorticoid treatment, to generate a predictive computational strategy based on systems biology. Contrasting mRNA and miRNAs intestinal expression profiles with updated molecular information related to UC and glucocorticoids, we were able to identify a mechanism of action (MoA) associated with corticosteroid failure in UC. ith the aim of transferring these results to clinical practice, the MoA-models created previously were implemented with plasmatic miRNAs profiles, to describe in silico non-invasive potential biomarkers of glucocorticoid refractoriness. Small RNA-seq analysis was perfomed using Illumina next generation sequencing and standard statistical criteria were applied to compare the miRNA profiles, incluidng paired samples before clucocorticoid treatment to the third day of the steroidal treatment. The selection these miRNA with predictive capacity was done using two complementary strategies: the first one using all the obtained miRNAs, and the second taking into account those miRNAs that are directly related to MoA, through various statistical restrictions (RELIEF, ENTROPY + CORRELATION, WILCOXON, ROC, and simple REGRESSION). These computational approaches from all miRNAs identified hsa-miR218-5p as the best to classify patients according their respond at basal time (Accuracy = 84.21%, Generalization Capability = 84.21%, Sensitivity = 100% and Specificity = 66.67%). In addition, the combination of this miRNA with hsa-miR6754-5p and hsa-miR4767, increases the diagnosis accuracy of the disease (Accuracy = 94.74%, Generalization Capability = 75.44%, Sensitivity = 70% and specificity = 81.48%). On the other hand, the combination of hsa-miR218-5p and the plasma levels of the Protein C Reactive increases the ability to classify patients towards their response to glucocorticoids up to 89%. Taking in account all this data, we can conclude that by means of a computer strategy based on Biology of Systems we have identified the plasmatic miR-218-5p as a potential biomarker to glucocorticoid response in UC before start the treatment.

Overall design

In total 46 samples were analyzed: 7 reference and 39 UC patient samples, derived from 27 different individuals (7 healthy controls and 20 patients). There were two patient groups based on glucocorticoid treatment response, composed of 10 responders and 10 non-responders respectively. Patient samples were collected at two different times: before and three days after glucocorticoid treatment. In total there were 19 sets of paired patient samples, before and after treatment from each of 19 diferent individual patients, and a single odd sample taken after treatment from the 20th patient.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
46 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. ANP32E, a Protein Involved in Steroid-Refractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach. Journal of Crohn's & colitis, 2019
Available

Metadata Quality Components

Analysis Readiness

Not ready
55% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • Critical dataset warnings must be resolved.
  • Secondary RNA assay context should be analyzed separately from ordinary bulk RNA-seq.

Next Steps

  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

Critical dataset warnings are present.

Assay context may require expert handling before DESeq2-style analysis.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context Inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Inflammatory bowel disease 46 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 30329026.
  • Publication context: ANP32E, a Protein Involved in Steroid-Refractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach.. Journal of Crohn's & colitis, 2019. PMID 30329026. DOI 10.1093/ecco-jcc/jjy171.

Cautions

  • Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%.
  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Small RNA, miRNA, circRNA, or extracellular-vesicle RNA context downgraded for primary mRNA tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because secondary RNA assays are not primary mRNA tissue RNA-seq.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Biofluid. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

97 fields

Sample Group Preview

46 rows shown
Show Hide
Study totals: Case 46 | Control 0 | Unassigned 0 | Excluded 0 | Ambiguous 0 46 rows shown
Group Role Accession Title Source / characteristics Reason
Inflammatory bowel disease Case GSM3476321 VC1 Plasma Disease state: Reference; Corticosteroid response: No IBD treatment; Collection time: No IBD treatment; Age (years): 56; Sex: Male; Individual: VC1; Sample type: Plasma Case marker detected.
Inflammatory bowel disease Case GSM3476322 VC2 Plasma Disease state: Reference; Corticosteroid response: No IBD treatment; Collection time: No IBD treatment; Age (years): 54; Sex: Female; Individual: VC2; Sample type: Plasma Case marker detected.
Inflammatory bowel disease Case GSM3476323 VC5 Plasma Disease state: Reference; Corticosteroid response: No IBD treatment; Collection time: No IBD treatment; Age (years): 68; Sex: Male; Individual: VC5; Sample type: Plasma Case marker detected.
Inflammatory bowel disease Case GSM3476324 VC6 Plasma Disease state: Reference; Corticosteroid response: No IBD treatment; Collection time: No IBD treatment; Age (years): 59; Sex: Female; Individual: VC6; Sample type: Plasma Case marker detected.
Inflammatory bowel disease Case GSM3476325 VC8 Plasma Disease state: Reference; Corticosteroid response: No IBD treatment; Collection time: No IBD treatment; Age (years): 56; Sex: Female; Individual: VC8; Sample type: Plasma Case marker detected.
Inflammatory bowel disease Case GSM3476326 VC9 Plasma Disease state: Reference; Corticosteroid response: No IBD treatment; Collection time: No IBD treatment; Age (years): 44; Sex: Female; Individual: VC9; Sample type: Plasma Case marker detected.
Inflammatory bowel disease Case GSM3476327 VC11 Plasma Disease state: Reference; Corticosteroid response: No IBD treatment; Collection time: No IBD treatment; Age (years): 71; Sex: Female; Individual: VC11; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476328 0074.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 59; Sex: Male; Individual: 74; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476329 1359.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 37; Sex: Female; Individual: 1359; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476330 1267.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 39; Sex: Male; Individual: 1267; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476331 1289.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 22; Sex: Male; Individual: 1289; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476332 0168.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 46; Sex: Female; Individual: 168; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476333 1306.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 60; Sex: Male; Individual: 1306; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476334 0773.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 25; Sex: Male; Individual: 773; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476335 0039.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 50; Sex: Male; Individual: 39; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476336 1229.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 43; Sex: Male; Individual: 1229; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476337 0285.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: Before glucocorticoid treatment; Age (years): 83; Sex: Male; Individual: 285; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476338 0714.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 26; Sex: Male; Individual: 714; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476339 1213.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 28; Sex: Female; Individual: 1213; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476340 1106.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 26; Sex: Female; Individual: 1106; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476341 0462.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 55; Sex: Male; Individual: 462; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476342 0577.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 82; Sex: Female; Individual: 577; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476343 1238.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 49; Sex: Female; Individual: 1238; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476344 1279.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 72; Sex: Male; Individual: 1279; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476345 0730.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 34; Sex: Female; Individual: 730; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476346 1193.C1 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: Before glucocorticoid treatment; Age (years): 32; Sex: Male; Individual: 1193; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476347 1306.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 60; Sex: Male; Individual: 1306; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476348 0773.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 25; Sex: Male; Individual: 773; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476349 0285.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 83; Sex: Male; Individual: 285; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476350 0039.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 50; Sex: Male; Individual: 39; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476351 1229.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 43; Sex: Male; Individual: 1229; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476352 0074.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 59; Sex: Male; Individual: 74; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476353 1267.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 39; Sex: Male; Individual: 1267; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476354 1289.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 22; Sex: Male; Individual: 1289; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476355 0168.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 46; Sex: Female; Individual: 168; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476356 1359.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 37; Sex: Female; Individual: 1359; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476357 0714.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 26; Sex: Male; Individual: 714; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476358 1213C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 28; Sex: Female; Individual: 1213; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476359 1106.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 26; Sex: Female; Individual: 1106; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476360 0462.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 55; Sex: Male; Individual: 462; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476361 0577.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 82; Sex: Female; Individual: 577; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476362 1238.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 49; Sex: Female; Individual: 1238; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476363 1279.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 72; Sex: Male; Individual: 1279; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476364 0730.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 34; Sex: Female; Individual: 730; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476365 1193.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 32; Sex: Male; Individual: 1193; Sample type: Plasma Case marker detected.
Ulcerative colitis Case GSM3476366 1416.C2 Plasma Disease state: UC; Corticosteroid response: Glucocorticoid non-responder; Collection time: 3rd day after starting Glucocorticoid treatment; Age (years): 30; Sex: Female; Individual: 1416; Sample type: Plasma Case marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.